


# Aniracetam





ANIRACETAM – DATA BASE

PRIMARY INFORMATION SERVICES

[WWW.PRIMARYINFO.COM](http://WWW.PRIMARYINFO.COM)

[MAILTO:PRIMARYINFO@GMAIL.COM](mailto:PRIMARYINFO@GMAIL.COM)

# Aniracetam



Aniracetam  
Classified as a smart drug **used in** alternative  
medicine to sharpen memory, improve  
concentration, and increase mental alertness

Aniracetam is used  
For Alzheimer's disease.

## ANIRACETAM – DATA BASE




### PRIMARY INFORMATION SERVICES

[WWW.PRIMARYINFO.COM](http://WWW.PRIMARYINFO.COM)

[MAILTO:PRIMARYINFO@GMAIL.COM](mailto:PRIMARYINFO@GMAIL.COM)



# Aniracetam



Aniracetam is anxiolytic

Helps reduce anxiety

Side effects of Aniracetam  
insomnia, headaches, anxiety,  
pain, vertigo, nausea,  
diarrhea.

# ANIRACETAM DATA BASE

## PRIMARY INFORMATION SERVICES



[WWW.PRIMARYINFO.COM](http://WWW.PRIMARYINFO.COM)

[MAILTO:PRIMARYINFO@GMAIL.COM](mailto:PRIMARYINFO@GMAIL.COM)





# Aniracetam



coa.pdf - Adobe Acrobat Reader DC  
File Edit View Window Help



## CERTIFICATE OF ANALYSIS

### Aniracetam

(N-anisoyl-2-pyrrolidinone)

Material Lot# 150701  
Country of Origin: China

Manufacture Date: 07/22/2015  
Retesting Date: 07/21/2017

#### Analysis

#### Claim

#### Result

#### Assay

≥ 98%

99.32%

#### Test

#### Claim

#### Result

Type here to search

# ANIRACETAM – DATA BASE




## PRIMARY INFORMATION SERVICES

[WWW.PRIMARYINFO.COM](http://WWW.PRIMARYINFO.COM)

[MAILTO:PRIMARYINFO@GMAIL.COM](mailto:PRIMARYINFO@GMAIL.COM)



# Aniracetam



Designing a Formulation of the Nootropic Drug Aniracetam Using 2-Hydroxypropyl—Cyclodextrin Suitable for Parenteral Administration

# ANIRACETAM

DATA BASE



# MATERIAL SAFETY DATA SHEET

## SECTION 1 — PRODUCT INFORMATION

|                      |  |
|----------------------|--|
| Product Identifier:  | Aniracetam   |
| Product Use:         | Research and laboratory purposes. Not for veterinary or human use.                                   |
| Supplier:            | Syntharise Chemical Inc.<br>7111 Syntex Drive, 3rd Floor,<br>Mississauga, Ontario, L5N 8C3<br>Canada |
| Emergency Contact:   | 3E Company   |
| Emergency Telephone: | 1-(800)360-3220  |

## SECTION 2 — HAZARDOUS INGREDIENTS

| Hazardous Ingredients | %    | CAS Number | LD50 of Ingredient  | LC50 of Ingredient |
|-----------------------|------|------------|---|--------------------|
| Aniracetam            | ≥98% | 72432-10-1 | LD <sub>50</sub> in rats, mice<br>(mg/kg): ~4500, >5000<br>orally (Cumin) | not available      |

## SECTION 3 — PHYSICAL DATA

|                      |   |
|----------------------|---|
| Physical State :     | Solid   |
| Odour & Appearance : | Odourless white powder                          |
| Molecular Weight:    | 219.24g/mol                                     |
| Molecular Formula:   | C <sub>12</sub> H <sub>13</sub> NO <sub>2</sub> |

ANIRACETAM  
DATA BASE



Type here to search



10:26  
06-08-2019



4



# Treatment of neurological conditions by the co-administration of **aniracetam** and l-alpha glycerylphosphorylcholine

United States Patent Application 20090176740 A1 · Filed: 12/01/2008 · Published: 07/09/2009

[Biblio](#) [Claims](#) [Description](#) [Citations](#) [PDF](#) [Combined](#)

**Aniracetam** (1-[(4-methoxybenzoyl)]-2-pyrrolidinone) is co-administered with the acetylcholine precursor 1-alpha glycerylphosphorylcholine (Alpha GPC, choline alfoscerate, choline alphoscerate) to potentiate cognition enhancing effects in healthy subjects and patients suffering from neurological conditions including Alzheimer's Disease (AD), attention deficit disorder (ADD), Parkinson's Disease, schizophrenia, vascular dementia, post stroke aphasia, anxiety disorders, cerebral atrophy, chronic alcoholism, Down syndrome, dyslexia, and various other neurodegenerative conditions. The co-administration of **aniracetam** (and other racetam derivatives including oxiracetam) with the acetylcholine precursor 1-alpha glycerylphosphorylcholine decreases negative side-effects such as severe headaches while

Inventors: Phillips II, Douglas James (Jupiter, FL, US)  
Attorney/Agent: Douglas II, Phillips J. (1100 Sioux Street, Jupiter, FL, 33458, US)  
App Num: 12/315255  
Pub Date: 07/09/2009  
File Date: 12/01/2008  
Referenced by: [View patents that cite this patent](#)  
Export Citation: [Click for automatic bibliography generation](#)  
Primary Class: 514/75  
Intl. Classes: **A61K31/66**

ANIRACETAM DATA BASE  
PRIMARY INFORMATION SERVICES  
[WWW.PRIMARYINFO.COM](http://WWW.PRIMARYINFO.COM)  
[MAILTO:PRIMARYINFO@GMAIL.COM](mailto:PRIMARYINFO@GMAIL.COM)

QUESTIONS ?

[MAILTO:PRIMARYINFO@GMAIL.COM](mailto:PRIMARYINFO@GMAIL.COM)

Primary Information Services

[www.primaryinfo.com](http://www.primaryinfo.com)